Vimian Group (0V0) Stock Overview
Engages in the animal health business worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
0V0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.67 |
| 52 Week High | SEK 4.16 |
| 52 Week Low | SEK 2.75 |
| Beta | 1.56 |
| 1 Month Change | 7.94% |
| 3 Month Change | 4.47% |
| 1 Year Change | 24.05% |
| 3 Year Change | -9.56% |
| 5 Year Change | n/a |
| Change since IPO | -58.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0V0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.6% | -1.8% | -3.0% |
| 1Y | 24.1% | -14.6% | 16.9% |
Return vs Industry: 0V0 exceeded the German Medical Equipment industry which returned -13.9% over the past year.
Return vs Market: 0V0 exceeded the German Market which returned 16.8% over the past year.
Price Volatility
| 0V0 volatility | |
|---|---|
| 0V0 Average Weekly Movement | 8.3% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 0V0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0V0's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,200 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| 0V0 fundamental statistics | |
|---|---|
| Market cap | €1.88b |
| Earnings (TTM) | €19.30m |
| Revenue (TTM) | €391.00m |
Is 0V0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0V0 income statement (TTM) | |
|---|---|
| Revenue | €391.00m |
| Cost of Revenue | €121.10m |
| Gross Profit | €269.90m |
| Other Expenses | €250.60m |
| Earnings | €19.30m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 18, 2025
| Earnings per share (EPS) | 0.037 |
| Gross Margin | 69.03% |
| Net Profit Margin | 4.94% |
| Debt/Equity Ratio | 29.6% |
How did 0V0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/13 14:39 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vimian Group AB (publ) is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Hassan Al-Wakeel | Barclays |
| Blanka Porkolab | Barclays |